Skip to Content

Hydrochlorothiazide / olmesartan Side Effects

Not all side effects for hydrochlorothiazide / olmesartan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to hydrochlorothiazide / olmesartan: oral tablet

In addition to its needed effects, some unwanted effects may be caused by hydrochlorothiazide / olmesartan. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking hydrochlorothiazide / olmesartan:

Less common
  • Bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or cloudy urine
  • blurred vision
  • chest pain
  • difficult, burning, or painful urination
  • flushed, dry skin
  • frequent urge to urinate
  • fruit-like breath odor
  • increased hunger
  • increased urination
  • joint pain, stiffness, or swelling
  • lower back, side, or stomach pain
  • rapid weight gain
  • sweating
  • swelling of the feet or lower legs
  • tingling of the hands or feet
  • troubled breathing
  • unexplained weight loss
  • unusual weight gain or loss
  • Swelling or puffiness of the face
Incidence not known
  • Convulsions
  • decrease in the amount of urine
  • diarrhea (severe) with weight loss
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position
  • rash

Some of the side effects that can occur with hydrochlorothiazide / olmesartan may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Back pain
  • body aches or pain
  • chills
  • cough
  • difficulty with breathing
  • ear congestion or pain
  • fever
  • headache
  • head congestion
  • hoarseness or other voice changes
  • loss of voice
  • runny or stuffy nose
  • sneezing
  • sore throat
Less common
  • Acid or sour stomach
  • belching
  • difficulty with moving
  • dizziness or lightheadedness
  • feeling of constant movement of self or surroundings
  • heartburn
  • indigestion
  • joint pain, stiffness, or swelling
  • loss of appetite
  • muscle pain or stiffness
  • pain, swelling, or redness in the joints
  • sensation of spinning
  • stomach discomfort or upset
  • weakness
Incidence not known
  • Diarrhea
  • muscle pain or stiffness
  • nervousness
  • weakness or heaviness of the legs

For Healthcare Professionals

Applies to hydrochlorothiazide / olmesartan: oral tablet


The most common side effect was dizziness.[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache
Uncommon (0.1% to 1%): Syncope

Common (1% to 10%): Dizziness, headache
Postmarketing reports: Lightheadedness, paresthesia

Common (1% to 10%): Dizziness, headache[Ref]


Common (1% to 10%): Bronchitis, pharyngitis, sinusitis, upper respiratory tract infection, coughing, nasopharyngitis

Common (1% to 10%): Bronchitis, nasopharyngitis, pharyngitis
Uncommon (0.1% to 1%): Sinusitis, upper respiratory tract infection, cough
Frequency not reported: Pneumonitis, pulmonary edema

Common (1% to 10%): Bronchitis, nasopharyngitis, sinusitis, upper respiratory tract infection, cough, pharyngitis, rhinitis[Ref]


Common (1% to 10%): Vertigo, Influenza-like symptoms, chest pain, fatigue, peripheral edema
Uncommon (0.1% to 1%): Weakness
Postmarketing reports: Asthenia, lethargy, malaise

Common (1% to 10%): Vertigo, influenza-like symptoms
Uncommon (0.1% to 1%): Chest pain, fatigue, peripheral edema
Frequency not reported: Weakness, fever

Common (1% to 10%): Vertigo, chest pain, fatigue, influenza-like symptoms, peripheral edema, pain
Postmarketing reports: Asthenia, lethargy, malaise[Ref]


Common (1% to 10%): Diarrhea, gastroenteritis, nausea, abdominal pain, dyspepsia
Postmarketing reports: Sprue-like enteropathy, vomiting

Uncommon (0.1% to 1%): Diarrhea, dyspepsia, nausea, gastroenteritis
Frequency not reported: Sialadenitis, cramping, gastric irritation
Postmarketing reports: Constipation

Common (1% to 10%): Diarrhea, dyspepsia, nausea, gastroenteritis, abdominal pain
Postmarketing reports: Vomiting, sprue-like enteropathy[Ref]


Common (1% to 10%): Back pain, creatine phosphokinase increased, arthralgia, arthritis, myalgia
Uncommon (0.1% to 1%): Pain in limb, spinal disorder
Postmarketing reports: Rhabdomyolysis

Common (1% to 10%): Arthralgia, back pain, pain in limb
Uncommon (0.1% to 1%): Spinal disorder
Frequency not reported: Muscle spasm

Common (1% to 10%): Arthralgia, back pain, pain in limb, arthritis, skeletal pain, creatine phosphokinase increased
Uncommon (0.1% to 1%): Spinal disorder, myalgia
Postmarketing reports: Rhabdomyolysis[Ref]


Common (1% to 10%): Hyperlipemia, hyperglycemia, blood uric acid increased, hyperuricemia
Uncommon (0.1% to 1%): Blood glucose increased, blood potassium decreased, blood potassium increased, hypertriglyceridemia
Postmarketing reports: Hyperkalemia

Common (1% to 10%): Blood glucose increased, blood potassium decreased
Uncommon (0.1% to 1%): Blood uric acid increased
Frequency not reported: Hyperglycemia, glycosuria, hyperuricemia
Postmarketing reports: Anorexia, loss of appetite

Common (1% to 10%): Hypertriglyceridemia, hyperglycemia, hyperuricemia
Uncommon (0.1% to 1%): Blood glucose increased, blood potassium decreased, blood uric acid increased
Rare (less than 0.1%): Hyperkalemia
Frequency not reported: Hypercholesterolemia[Ref]


Common (1% to 10%): GGT increased, AST increased, ALT increased

Uncommon (0.1% to 1%): ALT increased, AST increased, GGT increased
Frequency not reported: Pancreatitis, intrahepatic cholestatic jaundice

Common (1% to 10%): ALT increased, AST increased, GGT increased[Ref]


Common (1% to 10%): Hematuria, urinary tract infection

Common (1% to 10%): Urinary tract infection

Common (1% to 10%): Urinary tract infection, hematuria[Ref]


Uncommon (0.1% to 1%): Anxiety, insomnia

Uncommon (0.1% to 1%): Anxiety, insomnia
Frequency not reported: Restlessness
Postmarketing reports: Sleep disturbances, depression

Common (1% to 10%): Insomnia
Uncommon (0.1% to 1%): Anxiety[Ref]


Common (1% to 10%): Rash, facial edema
Uncommon (0.1% to 1%): Eczema
Postmarketing reports: Alopecia, pruritus, urticaria

Frequency not reported: Purpura, photosensitivity, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis
Postmarketing reports: Rash, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus, erythematosus

Uncommon (0.1% to 1%): Rash
Postmarketing reports: Alopecia, pruritus, urticaria[Ref]


Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Viral infection
Frequency not reported: Angioedema
Postmarketing reports: Anaphylactic reactions

Uncommon (0.1% to 1%): Influenza, viral infection
Frequency not reported: Anaphylactic reactions

Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Viral infection
Postmarketing reports: Angioedema, anaphylactic reactions[Ref]


Uncommon (0.1% to 1%): Blood creatinine increased
Postmarketing reports: Acute renal failure

Uncommon (0.1% to 1%): Blood creatinine increased
Frequency not reported: Renal failure, renal dysfunction, interstitial nephritis

Uncommon (0.1% to 1%): Blood creatinine increased
Postmarketing reports: Acute renal failure[Ref]


Uncommon (0.1% to 1%): Palpitations, hypotension, orthostatic hypotension

Frequency not reported: Vasculitis, cutaneous vasculitis
Postmarketing reports: Cardiac arrhythmias, postural hypotension

Uncommon (0.1% to 1%): Tachycardia, angina pectoris
Rare (less than 0.1%): Hypotension[Ref]


Frequency not reported: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia
Postmarketing reports: Bone marrow depression[Ref]


Ocular side effects have included idiosyncratic reactions to the hydrochlorothiazide component resulting in acute transient myopia and acute angle-closure glaucoma.[Ref]


1. "Product Information. Benicar HCT (hydrochlorothiazide-olmesartan)." Sankyo Parke Davis, Parsippany, NJ.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.